CYP2C19 and rheumatoid arthritis: Furthermore, since there has been an association between greater reduction in RA disease activity in patients with higher plasma teriflunomide steady state concentration [3,15,16], CYP2C19 intermediate/poor metabolizers may have an especially adverse risk:benefit ratio by virtue of a higher risk of cessation with side effects and a reduced likelihood of therapeutic benefit.